Authors: Bromidge, SM Clarke, SE Gager, T Griffith, K Jeffrey, P Jennings, AJ Joiner, GF King, FD Lovell, PJ Moss, SF Newman, H Riley, G Rogers, D Routledge, C Serafinowska, H Smith, DR

Citation: Sm. Bromidge et al., Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: Identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134), BIOORG MED, 11(1), 2001, pp. 55-58

Authors: Jerman, JC Brough, SJ Gager, T Wood, M Coldwell, MC Smart, D Middlemiss, DN

Citation: Jc. Jerman et al., Pharmacological characterisation of human 5-HT2 receptor subtypes, EUR J PHARM, 414(1), 2001, pp. 23-30

Authors: Routledge, C Bromidge, SM Moss, SF Price, GW Hirst, W Newman, H Riley, G Gager, T Stean, T Upton, N Clarke, SE Brown, AM Middlemiss, DN

Citation: C. Routledge et al., Characterization of SB-271046: A potent, selective and orally active 5-HT6receptor antagonist, BR J PHARM, 130(7), 2000, pp. 1606-1612

Authors: Bromidge, SM Brown, AM Clarke, SE Dodgson, K Gager, T Grassam, HL Jeffrey, PM Joiner, GF King, FD Middlemiss, DN Moss, SF Newman, H Riley, G Routledge, C Wyman, P

Citation: Sm. Bromidge et al., 5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A potent, selective, and orally bioavailable 5-HT6 receptor antagonist, J MED CHEM, 42(2), 1999, pp. 202-205

Authors: Watson, J Brough, S Coldwell, MC Gager, T Ho, M Hunter, AJ Jerman, J Middlemiss, DN Riley, GJ Brown, AM

Citation: J. Watson et al., Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors, BR J PHARM, 125(7), 1998, pp. 1413-1420